Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- LDP Subcommittee Holds Hearing on Unification of Dispensing Fees
July 25, 2011
- “Biosimilars Era”Coming to Japan: Mr Sawai of JGA
July 25, 2011
- JPA to Collect ADR Avoidance Case Reports from Pharmacies
July 25, 2011
- Merck Serono to Enter 2nd High Growth Stage after Stable Growth in 2011-2012: President Smith
July 25, 2011
- No Major Obstacle to Japan's Participation in PIC/S: Chairman Graberg
July 25, 2011
- Teva Obtains All Shares from Taiyo Pharm. for ¥74 Bil.
July 25, 2011
- APEX to Build Up Nationwide Network
July 25, 2011
- Drug Production in March Down as Much as 65% in 3 Quake-hit Prefectures: Korosho
July 25, 2011
- Rivaroxaban Approved for Prevention of DVT in the US
July 25, 2011
- HPB Issues Notification Aimed at Increasing Efficiency of Clinical Trials
July 25, 2011
- J-CKDI Predicts Dialysis Patients to Decrease after Peak in 2017
July 25, 2011
- Antiepileptic Agent Rufinamide Approved in Canada: Eisai
July 18, 2011
- Over 70% of Women Aware of HPV Vaccine: Survey
July 18, 2011
- FDA Committee Recommends Withdrawal of Breast Cancer Indication from Avastin
July 18, 2011
- Bristol-Myers to Create Friendlier Work Environment for Women
July 18, 2011
- Council on Unapproved Drugs to Revise Assessment Criteria
July 18, 2011
- STATISTICS
July 18, 2011
- Sales of Ethical Drugs Up 7.5% in May: Crecon & Research Consulting
July 18, 2011
- Bayer Aiming for Top-10 Spot in Global Ethical Drug Market by 2015
July 18, 2011
- JACDS, JPA to Cooperate Regarding nternet Drug Sales, Unification of Basic Dispensing Fees
July 18, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…